Seer (SEER) FCF Yield % : -42.23 (As of May. 18, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Seer FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Seer's Trailing 12-Month Free Cash Flow is $-58.13 Mil, and Market Cap is $137.02 Mil. Therefore, Seer's FCF Yield % for today is -42.23%.

The historical rank and industry rank for Seer's FCF Yield % or its related term are showing as below:

SEER' s FCF Yield % Range Over the Past 10 Years
Min: -76.72 Med: -16.82 Max: -1.51
Current: -42.23

During the past 6 years, the highest FCF Yield % of Seer was -1.51%. The lowest was -76.72%. And the median was -16.82%.

SEER's FCF Yield % is ranked worse than
72.96% of 1557 companies
in the Biotechnology industry
Industry Median: -14.14 vs SEER: -42.23

Seer's FCF Margin % for the quarter that ended in Mar. 2024 was -369.97%.

Seer FCF Yield % Historical Data

The historical data trend for Seer's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer FCF Yield % Chart

Seer Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-0.76

-3.77

-19.32

-53.21

Seer Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-31.62	-23.86	-52.65	-38.57	-36.34

Competitive Comparison of Seer's FCF Yield %

For the Biotechnology subindustry, Seer's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seer's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Seer's FCF Yield % falls into.

Seer FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Seer's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-66.374	/	124.739478
	=	-53.21%

Seer's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-11.21	*	4	/	123.37973
	=	-36.34%

Seer FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Seer FCF Yield % Related Terms

Thank you for viewing the detailed overview of Seer's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Seer (SEER) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065

Website

https://www.seer.bio

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.

Executives

Elona Esq. Kogan	officer: General Counsel and Secretary	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad	director, 10 percent owner, officer: CEO and Chair of the Board	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas	officer: Chief Commercial Officer	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn	officer: Chief Financial Officer	3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan	director, officer: President & COO	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani	director	C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz	director	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer	director	C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005